このエピソードについて
FDA-cleared single-step immunoblot tests built on recombinant antigens from multiple Borrelia species detected nearly twice as many early Lyme disease cases as standard two-tier testing. Joseph J. Burrascano Jr, MD, offers insights into what the new tests mean for clinicians.
英語
アメリカ合衆国
文字起こし 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
このポッドキャストの他のエピソード
Artificial intelligence is increasingly reshaping clinical decision-making, and a new generation of point-of-care tools is targeting one of healthcare’s most persistent challenges: antimicrobial stewardship. In a recent podcast discussion, Eolas Medical Founder and CEO Declan Kelly, MBBS, outline…
A new multiplex blood-screening assay is streamlining transfusion safety by enabling simultaneous detection and discrimination of HIV, HBV, HCV, and hepatitis E in a single test, helping laboratories improve efficiency, reduce turnaround times, and strengthen blood supply resilience amid ongoing do…
Accurate, rapid diagnostics capable of distinguishing Ebola from other febrile illnesses are essential to controlling the ongoing Bundibugyo Ebola outbreak, with BioFire Defense deploying its Global Fever Special Pathogens Panel to affected regions in partnership with local governments. Chuck Coope…
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
免責: このページに埋め込まれているポッドキャストとアートワークは Contagion からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。
